SPA approved for phase III trial (evaluating efficacy in combo w/ lenalidomide+low-dose DEX vs. lenalidomide and low-dose DEX alone), which is expected to begin mid-2010 (2/10); touted to be a potential blockbuster; initiated phase III trial in relapsed multiple myeloma in combo w/ Revlimid + low dose dexamethasone (7/10); plans to file for accelerated approval (7/10)
Brand N/A Generic carfilzomib
Company name Onyx Product type Speciality
Therapeutic category Immunologic agents Key uses multiple myeloma
Other Uses advanced solid tumors Drug Class proteasome inhibitor
Dosage From IV push Expected Approval 2012+
FDA Filing N/A Last Update date July 28,2010
Link to news article
Link to clinicaltrials.gov
Link to press releases